Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of GoodwillAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avanos Medical (AVNS) Cash from Operations (2016 - 2025)

Avanos Medical (AVNS) has disclosed Cash from Operations for 13 consecutive years, with 28200000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations fell 51.3% to 28200000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 74700000.0 through Dec 2025, down 25.82% year-over-year, with the annual reading at 74700000.0 for FY2025, 25.82% down from the prior year.
  • Cash from Operations hit 28200000.0 in Q4 2025 for Avanos Medical, up from 14000000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 57900000.0 in Q4 2024 to a low of 8000000.0 in Q1 2024.
  • Historically, Cash from Operations has averaged 19300000.0 across 5 years, with a median of 23100000.0 in 2021.
  • Biggest five-year swings in Cash from Operations: soared 4636.36% in 2021 and later plummeted 477.78% in 2023.
  • Year by year, Cash from Operations stood at 52100000.0 in 2021, then crashed by 35.32% to 33700000.0 in 2022, then plummeted by 62.31% to 12700000.0 in 2023, then skyrocketed by 355.91% to 57900000.0 in 2024, then tumbled by 51.3% to 28200000.0 in 2025.
  • Business Quant data shows Cash from Operations for AVNS at 28200000.0 in Q4 2025, 14000000.0 in Q3 2025, and 6800000.0 in Q2 2025.